GlaxoSmithKline Pharmaceuticals Limited has announced the resignation of Mr. Juby Chandy from his dual roles as Whole-Time Director and Chief Financial Officer. The resignation became effective from the close of business hours on March 11, 2026, following his appointment to a senior regional position within the GSK group.

Leadership Transition Details

The pharmaceutical company disclosed Chandy's departure through a regulatory filing dated March 16, 2026, submitted to both BSE Limited and the National Stock Exchange of India Limited. The disclosure was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Career Advancement Within GSK Group

Chandy's resignation stems from his appointment as Finance Head for the Asia Pacific region at GSK, representing a significant career advancement within the global pharmaceutical organization. In his resignation letter dated March 2, 2026, addressed to the Board of Directors, Chandy requested the Board to complete necessary filings with relevant Government Authorities and regulatory bodies.

Acknowledgment and Transition

The outgoing CFO expressed sincere gratitude to the Board of Directors and Managing Director for their support and guidance throughout his tenure. Chandy described his service to the organization as a privilege and extended wishes for GSK India's continued growth and success.

The company secretary, Ajay Nadkarni, Vice President – Administration, Real Estate & Company Secretary, signed the regulatory disclosure on behalf of GlaxoSmithKline Pharmaceuticals Limited. The filing referenced an earlier announcement dated March 2, 2026, indicating the company had previously communicated about this leadership change.

Regulatory Compliance

GlaxoSmithKline Pharmaceuticals Limited, incorporated in 1924 with CIN L24239MH1924PLC001151, ensured full compliance with SEBI Listing Regulations by promptly disclosing the senior management change. The company maintains its headquarters at GSK House, Dr. Annie Besant Road, Worli, Mumbai, and continues its operations under the new leadership structure.

GlaxoSmithKline Pharmaceuticals Limited has issued a postal ballot notice seeking shareholder approval for the appointment of Ronojit Biswas as Whole-Time Director and Chief Financial Officer. The company sent the postal ballot notice to stock exchanges on March 7, 2026, in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Postal Ballot Process and Timeline

The notice is being distributed electronically to shareholders whose email addresses are registered with the company or depositories as of the cut-off date of February 27, 2026. The Board of Directors appointed P.N. Parikh (FCS 327) and Jigyasa Ved (FCS 6488) of Parikh & Associates as scrutinizers to conduct the postal ballot process.

Appointment Details and Remuneration Structure

The postal ballot seeks approval for two ordinary resolutions: first, the appointment of Biswas as Director, and second, his appointment as Whole-Time Director & CFO for three years from April 1, 2026, to March 31, 2029. The Board of Directors initially appointed Biswas as Additional Director during their meeting on March 2, 2026, subject to shareholder approval.

Professional Background and Qualifications

Ronojit Biswas, aged 51, brings over 25 years of experience with GSK across international markets including India, Vietnam, Singapore, Brazil, and the UK. He started his career with GSK in India as a Management Trainee in 1999 and most recently served as Senior Finance Director – Global Product Strategy, based in Singapore. His previous roles include CFO positions for GSK's Brazil and Vietnam businesses, and Regional Controller for GSK's International region.

Biswas holds a Post Graduate Program in Management (Finance) from Management Development Institute, Gurgaon, and a Bachelor's degree in Commerce (Hons.) from St. Xavier's College, Kolkata.

Leadership Transition and Regulatory Compliance

The appointment follows the planned transition of current CFO Juby Chandy, who will step down from his roles as Whole-Time Director and CFO on March 11, 2026, to assume a new leadership position focusing on APAC Finance within the GSK Group. The company confirmed that Biswas is not related to any existing Directors and has not been debarred by any regulatory authority.

The appointment requires ordinary resolution approval from shareholders, with voting rights proportional to shareholding as of the cut-off date. The e-voting facility is provided through KFin Technologies Limited, with detailed instructions available on the company's website and stock exchange platforms.